

# A randomized phase II study of early nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer


Tateaki Naito MD. Shuichi Mitsunaga MD. Satoru Miura MD. Toshimi Inano RD. Taro Okavama PT. Takako Mouri RN, and Koichi Takavama MD Shizuoka Cancer Center, Nijoata Cancer Center Hospital, National Cancer Center Hospital East, and Kyoto Prefectural University of Medicine

Japanese Association of Supportive Care in Cancer Cachexia Study Group

#### **OUR HYPOTHESIS**



#### **OUTCOME**



# **BACKGROUD** B C () ()

| Variables                         | NEXTAC       | CONTROL    |
|-----------------------------------|--------------|------------|
| N                                 | 64           | 65         |
| Median Age (range)                | 75.5 (70-87) | 76 (70-86) |
| Female gender (%)                 | 19 (30)      | 24 (37)    |
| PS 0                              | 45 (45)      | 25 (39)    |
| 1                                 | 31 (48)      | 37 (57)    |
| 2                                 | 4 (6)        | 3 (5)      |
| Cancer Lung                       | 45 (70)      | 46 (71)    |
| Pancreatic                        | 19 (30)      | 19 (29)    |
| Stage Locally advanced            | 12 (19)      | 6 (9)      |
| Metastatic                        | 52 (81)      | 59 (91)    |
| Cytotoxic regimen                 | 40 (62)      | 40 (62)    |
| Targeted or Immunotherapy         | 24 (38)      | 25 (39)    |
| Cancer cachexia (Fearon criteria) | 31 (48)      | 36 (55)    |
| Muscle depletion (Martin L, 2015) | 40 (66)      | 50 (78)    |

No statistical differences in any variables between the groups

#### SECOMDARY ANALYSIS

| Secondary endpoints & Safety |            |            |         |  |  |
|------------------------------|------------|------------|---------|--|--|
| Changes T1 to T4             | NEXTAC     | CONTROL    | P-value |  |  |
| Body weight                  | -1.2±0.4   | -0.7±0.4   | 0.660   |  |  |
| Lumbar SMI                   | -1.8±0.4   | -0.7±0.4   | 0.0232* |  |  |
| Physical function            |            |            |         |  |  |
| Hand grip strength           | -1.3±0.3   | -0.7±0.3   | 0.5242  |  |  |
| SPPB score                   | -0.1±1.5   | -0.2±0.4   | 0.6932  |  |  |
| 5 sit-to-stand test time     | 0.2±2.3    | 0.2±2.7    | 0.6042  |  |  |
| Nutrtion                     |            |            |         |  |  |
| Full MNA score               | 0.7±0.6    | 0.4±0.5    | 0.3949  |  |  |
| Calorie intake               | 127.2±59.0 | -41.6±50.8 | 0.0387* |  |  |
| Protein intake               | 2.5±2.5    | -0.7±2.5   | 0.3703  |  |  |
| Overall survival (median)    | 547 days   | 604 days   | 0.9836  |  |  |

- . Intervention-related adverse events (all Grade 1 in CTC-AE ver 4.0)
- fatigue 5 (7.8%), Joint pain 3 (4.7%), Dyspnea 2 (3.1%), Muscle pain 1 (1.6%)

#### STUDY DESIGN

We aimed to elucidate whether the early multimodal intervention (NEXTAC program) improves functional prognosis in elderly patients with a high-risk for cancer cachexia. Weight loss was not required

. Majority were at the time of first cancer diagnosis

#### Eligibility

- 1. ≥ 70 years old
- : The earliest possible timing of cachexia intervention 2. Newly diagnosed advanced non-small cell lung or pancreatic cancer
- 3. Planned to receive the first-line systemic chemotherapy (including targeted Tx)
- 4. ECOG-PS 0-2
- 5. Without disability in Katz-index
- 6. Without organ complications or symptomatic brain or bone mets

Miura S. BMC Cancer. PMID: 31151425

## INTERVENTION

| NEXTAC intervention Mura S. BMC Cancer. 2019 PMID: 31151 Natio T. JCSM. 2018 PMID: 30334 |  |  |                         |
|--|--|--|-------------------------|
| Interventions  | Nutrition  | Exe                                      | rcise                   |
| interventions  | Nutrition  | Resistance training                      | Physical activity       |
| Instructors  | Registered dietitian   | Physiotherapists, Nurses, or Physicians  |                         |
| Duration   | 4 Sessions every 4±2 weeks (total 12 weeks)  |  | 2 weeks)                |
| Session time   | 20-30 minutes for each session   |  |                         |
|  | <ul> <li>Nutritional assessment</li> </ul>   | <ul> <li>Physical assessments</li> </ul> | Lifestyle assessments   |
|  | <ul> <li>Nutritional advice</li> </ul>   | · Home-based light intensity             | y · Accelerometer-based |
| Contents   | <ul> <li>NIS counseling</li> </ul>   | resistance training in lowe              | r counseling            |
|  | BCAA-rich ONS  | limbs                                    | Behavioral Change Tech  |
| NEXTAC sho   | NEXTAC showed an excellent compliance & adherence in the previous NEXTAC-ONE feasibility study |  |                         |
| Using own body weight  a Visights  Acceleronater Uniconder (Stauken)                     |  |  |                         |
| Inner Power8   | (Otsuka Pharmaceutics)   |  |                         |

#### **OUTCOMES**

| Variables   | NEXTAC        | CONTROL      |
|---|---------------|--------------|
| N   | 64            | 60           |
| No. of attendance to sessions, median (range)                   | 8 (4-8)       | -            |
| Participation ratio (%)   | 63 (98.4)     |              |
| Supplements consumption (%)                                     | 88 (73 - 97)  | -            |
| Exercise performance (%)  | 86 (53 - 96)  | -            |
| % of Accerelometer wearing day (≥5 h/day, %)                    | 98 (81 - 100) | 95 (78 - 97) |
| No. of patients who increased indoor activity (or full), n (%)  | 15 (23.8)     | 23 (38.3)    |
| No. of patients who increased outdoor activity (or full), n (%) | 25 (39.7)     | 25 (41.7)    |

Compliance to Exercise & Supplements was excellent in NEXTAC group However, there are no statistical differences in behavioral change parameters between the groups

# **Exploratory post-hoc analysis** What is the meaning of adding exercise to nutrition? Change in Protein intake Change in Protein intake

Exercise may sensitize the muscle to nutrition

#### DISCUSSION





### Primary Endpoint

# Secondary Endpoints

- 1. Weight, Lumbar skeletal muscle index
- Physical function (HGS, SPPB, 5 sit-to-stand test) Nutrition (MNA, oral intake)
- 4. Overall survival

Miura S. BMC Cancer. 2019. PMID: 31151425 Trial registration No. UMIN00002880

### Physical activity Promotion

|            | Physical activity Promotion   |  |  |  |
|------------|-------------------------------|--|--|--|
|            | 4 steps                       | Examples   |  |  |
|            | Goal setting &<br>Feedback    | Set step goal: baseline + 2000 steps     Self-monitoring: taking diary   |  |  |
| 九          | Action planning               | Regular walking & House chores     Stay in the job                       |  |  |
| 3          | Active management of symptoms | Cosmetic problems (e.g. Skin rash)     Physical problems (e.g. Diarrhea) |  |  |
| <b>₽</b> ~ | Fall prevention               | Do not use sandals or slippery shoes     Maintain a clutter-free floor   |  |  |

Mouri T & Naito T, Asia Pac J Oncol Nurs, 2018 [E-pub ahead of print]

#### Primary endpoint: Disability-free survival



#### Conclusion

- Early multimodal intervention (NEXTAC) DID NOT
- Prevent disability
- · Increase weight and skeletal muscle
- · Improve physical functions
- · Improve nutritional status except for calorie intake

What have we learned from this study?



. Much stronger anabolic intervention may be needed such as high-intensity exercise or adding anamorelin to modify the functional trajectory of cancer

Thank you for your attention (^^)